Lupin and DKSH sign exclusive licensing and supply agreement to market five biosimilar candidates in Philippines

Lupin and DKSH today signed an exclusive licence and supply agreement to commercialise five of Alvotech’s proposed biosimilars in the Philippines. The biosimilars planned under this agreement include biosimilar Prolia (denosumab 60mg/ml), Xgeva (denosumab 70 mg/ml), Simponi (golimumab) and Eylea (aflibercept) as well as two undisclosed proposed biosimilars for immunology and oncology, the companies notified via a joint statement.

According to the agreement, Lupin’s subsidiary in Philippines, Multicare Pharma, will file for marketing approval and be responsible for distribution and commercialisation of the biosimilars, once approved, the statement said.

It also said that these reference products are used to treat disorders relating to bone disease, oncology, immunology and ophthalmology. This agreement enhances Multicare’s oncology, rheumatology, gastroenterology and ophthalmology, portfolio, which currently consists of three biosimilar candidates and over 50 generic medicines.